Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study.

ABSTRACT:

Background

 There is limited information on antiviral therapy for hepatitis B virus (HBV) infection among pregnant women coinfected with human immunodeficiency virus (HIV) and HBV.

Methods

 A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China. The HBV virological response was compared in study arms.

Results

 The median decline in the HBV DNA level was 2.60 log₁₀ copies/mL in the TDF/3TC arm and 2.24 log₁₀ copies/mL in the 3TC arm (P = .41). All women achieved HBV DNA levels of <6 log₁₀ copies/mL at delivery.

Conclusions

 Initiation of either regimen led to achievement of HBV DNA levels below the threshold associa

SUBMITTER: Wang L 

PROVIDER: S-EPMC11264234 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature